www.9882009.com_扠痔軓氈厙夥源喃硉笢陑:毞精豻塗惘珨撫惆ㄩ荅瞳閉65砬桴鸗蠵芼忸7200勀

www.9882009.com_扠痔軓氈厙夥源喃硉笢陑

2019-11-13 22:23:20

趼极:梓袧

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

﹛﹛Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.Advancing Oncology Research Through Clinical Trials#梓枙煦賃#Fewinnovationshavehelpedasmanyastheadventofthemodernclinicaltrial,especiallyincancerresearch.Withouttheseimportantstudies,doctors,regulators,patientsandcaregiverswouldnotbeabletodeterminewhatkindsofmedicinesmayhelppatients,orthepotentialrisks.Whiletheideathatwecancarefullyevaluatenewmedicinesistakenforgrantedtoday,theclinicaltrialasitisunderstoodtodaydatesbackonlytothe1940s.Priortothattime,hucksterscould每anddid每pushuselessorharmless※cures§onanyone.It'snocoincidencethatthegreatleapsforwardinmedicine,suchasantibiotics,arecloselylinkedwiththeadoptionofclinicaltrialsasthegoldstandardforunderstandingamedicine*seffects.Thebasicfoundationsoftherandomized,blindedclinicaltrial每comparingdifferentgroupsofotherwise-similarpatientsandensuringthatneitherdoctornorpatientisawareofwhoreceiveswhattreatment每haveproventheirvalue.ButourrecentworkatMSDisfocusedonensuringthattheclinicaltrialssystemadvancesandworksmoreeffectively.Quicker,smarterwaysofconductingclinicaltrialsmeansthatwecananswerscientificquestionsmorequicklyandmoreconfidently,allowingmorepatientsaccesstomedicinesthatmaypotentiallyhelpthem.Insomecases,wehaveworkedcloselywithregulatorstomodifyongoingtrialstoenrollmorepatientsandgathermoredata.NewFDArulesaround※breakthrough§productshaveallowedmorecollaborationwiththeFDA,andthiskindofcollaborationhashelpedMSDandothersinthepharmaceuticalindustrytoquicklygatherthedataneededtodemonstratethepotentialbenefitofnewtreatmentoptions.Ourimmuno-oncologyresearchprogramhasbeenoneareawherewe*vebeenabletousethesenewtools.Wehavehadtheopportunity每whentheearlytrialsshowpromise每toexpandstudiestogatheradditionalhigh-qualitydata,helpingadvancethepotentialforbringingmedicinestocancerpatients.ThedesignofMSD'soncologytrials,too,isbecomingmoreinnovative.Wehavemadeimportantstridesindevelopingnewtrialdesignsthatallowustoevaluatemultipletypesofcancersinonestudy.This,inturn,makesitmorelikelythatwecanidentifypotentialnewmedicinesinamoreefficientmanner.Theyearstocomearelikelytoseemoresuchtrialshelpingustobetteranswerquestionsonthebestwaytotreatcancer.Butclinicaltrialscanonlyadvancecancerresearchifpatientsvolunteertoparticipate.MSDiscommittedtohelpingeducatepatients,doctorsandcaregiversaboutoncologyclinicaltrials.

孮帢鉏迤滴ww.9882009.com_扠痔軓氈厙夥源喃硉笢陑扦衭厙ㄩ帤冪忨迆輓譙肴
壽瑩棵 >>

樟哿堐黍

陔恓

趕枙

藷芢熱

壽衾扂蠅 薊炵扂蠅 唳享驨 厙桴華芞
啃桴啃吨: 捚粔忑窒粒蚚iPhone鼴扜腔萇荌▲墅怚◎撈蔚羲噩 剢細怹轔桵梇噤埰祩簽鶺謠眈5堎26楖快楙飌 匙鑫掘3爛喳ぢ韁夢8檔藹紸ㄐ涴輸陑瓷笝衾壺賸 箝毞摩芶埻雁岈酗掩羲壺絨戮峊寞梩蛂滇詻ヴ伎蝠眢 儔陲蒩苤條ㄩ盄狟婬婖儔陲模萇筍祥峈賸盄狟奧盄狟 笢弊漆俋楷桯ㄩ忑撫冪茠祛瞳86.8砬誠啋肮掀崝5.3# 陔唳跺劼儽鑄邪5堎奻盄ㄩ眕縐欱縐蔚掩塊秶 陔檢夤荌芶▲陝嶺嶺◎踢砯荌傑陳栠湮埼傑虛Шき 栝俴數赫秶隅睿党隆12窒寞梒ㄩ踢諷鼠侗潼奪域楊婓蹈 陝爵恅軓傖蕾※郇鳶數赫§痴厥ч爛萇荌 票擘屬譫о楷恅竘童蚡厙衭芃そ※遜票擘屬赻蚕§ 躓陎峈毆瑰藷溫ィ栳眙岈珛ㄛ椒熗郱螂裔豜蚙悝盪怮腴ˋ 藝芞忒儂豢梗ㄩ蚕苤譙諉攫忮綴督昢娸卍櫛撓碣 隸Ч陲笝衾楷趕賸ㄩ蚗堈祥頗Ч秶埜馱995麼氪996 藝弊侗楊窒鼠羲賸\"籵塘藷\"覃脤惆豢僕448珜 杻檄ぱ蟀峞勒恣敝器熁壨遞噤柲踢3000嗣勀藝啋 羲攫ㄩ壽蛁籀眢抶瓚輛桯藝嘖笚侐詢羲 腌捚じ鳳ご菴珨弇け褁躉翅さ蒮鯞僱虡瑐庌蝺G 場腢晊摽虴狐l談鰍庈荽T豖堤鏍筳hF 勍誺撣忒迡耋К陓婬棒峈忒昫萸婝祥絞晟蹦炴 褪湮捅滄ㄩ2018爛僅噱瞳5.42砬啋肮掀崝酗24# 掉喊躓陬翋彶200勀\"猾諳煤\"ˋ衱衄陬翋釴奻竘э裔# 栦啋④ㄩPC庈部獗菁薊砑祥酕イ陬笢弊⑹埰Ж饃懈 蜓剆蜓﹜⑥剆⑥ㄩ※ロ檞珨測§掩撥堤笢莉論撰 羶衄涴弇90綴藝躓痔尪ㄛ憩羶衄涴棒窪韌桽え し彆氝樓※溜炩拉纂捲誰鋆睡肩羶忸鶶鷁鰍覜☆躅 怮嘉華莉俇傖堤忮怮嘉傑笢陑菴﹜侐釱昜珛100%例 党佼猿滄儂奀讀剿源砃嗆ヶ褽奻漆疏秞峎党鼠侗掩楠 ※ェ殤§謗爛嗣し彆詢籵笭党導疑 1.3勀腔殏詁そ忒儂蚚賸謗毞憩淝厗!陎ㄩ梗侉饒脯臚 壽阭哏赲汔撰眳暱韁襠蔚羲宎迵藝弊輛俴籀眢抶瓚 儔陲港僧溯虛楷汜嗣砐曹載ㄩ蚕囀訧わ珛曹峈俋妀芘訧 酗假膛ㄩ掉喊陬翋眒睿賤ㄛ窒藷隙茼樟哿蚳砐硒楊 れ菁瞳陎俴:黃模測燴縐杻捨毚祛歎閉詢淉葬珩腕邰衪 遠⑩奀惆:藝裂种笢弊悝氪ワ痐豇替ぢ輓笢弊侀埼擎繪 瞳腦弊暱梀輪8%揖250毞盄藻籵梀勘ぜ撰 藝3靡濂夥掩轎眥崠哏赲狟扽祥腕砃羸极課堯 栝弝:扠豪鳳萸⑩淏溢鄘朵檄媓帎漺騞褘樻宥魌 匙燮吤譫埏鳶婐場祭齬壺冼臥搎蟭毓酉襏窐譣獌 痐缺控見滿996§祜桶醱奻齡妗暱跦掛祥呾梁蹦 襯羹76佮で嗷母珃奴螢擭衝堈棧契髂阭 踏鹵控儔蔥迾极覜坁濮帤懂撓毞ァ恲苤盟隙汔 藝弊郗竘傾陝氿も荎弊馱絨鍰凈滌趕荎淉葬ㄩ猁毀勤ㄐ 3爛囀踡摹覂翻7棒帴-35笐旯桵儂嘟梤儂崝祫5殤 肵耀瑞疏徹綴ㄩ淉葬羲宎補啎鼴扜俋劓扡峊膘掩莞 陲儔兜堍頗蚔蚞婌奻掀衱岆※藝弊踢翋§砩祩极珋 銘鎮鼠票薊19佸等ㄩ藹萃鍰玴嶺蘆佴敕 壎贅勀峎堤忮垀厥今篚圉嘖爺今篧冱蛣5.73% Pinterest翋雄揤腴嘛硉ㄛ扦蝠黃褒忤霜悛奻庈硉鎘# 卼齪勤卼齪ㄩ旮匯睿茞嶺ㄛ闡珨跺符岆斕郔乾ˋ ▲貊佴嶺2ㄩ墅忤眳卼◎漆惆婬珋※卼氪躑綾§ 燠褫:植懂羶獗徹蝝佷切珛覺輛⑩岆⑩勦腔髡櫛 奻踢垀攜晊酗酴踢蝠眢奀潔枑詢芘訧魂埲僅 抻溼毞囧莉珛埶※僧蛔§漆睿漡蛜縗商襖寰婠棉 藝4堎督昢珛PMI蔥祫謗爛懂陔腴麼岆GDP崝厒狟視陓# 俋颯奪燴擁ㄩ2019爛3堎窅俴賦忮颯欄船61砬藝啋 詢埴埴汔撰絞鎔ㄐ涴勤軓氈死羅踼覘欶菸藐溼鷖鼳Х蓐蓎 2019奻漆陬桯抻奩ㄩJeepGladiator 陎殏詁忒儂嘟梤け堤俋羸ㄩし彆橈勤補祥堤涴岈嫁 梊蕾陔峚痔掩粒■晟﹜壽敕梖瘍脹揭离 鎮堁疪豗蹦瑞疏ㄩ淩淏996睿掩婀祅羶壽炵ㄐ厙衭旍廓 樂騰謠峚痔伄35呡④汜桽ㄛ燠苤韐泫黹滷獗救 宣_棪m煦R曇啞譙藩堎廣6ロ鼠踝滖豪 櫐俴ㄛ援埣醫冱朓漆藝腔餫劓鋪 鎮堁郔陔楷汒ㄩ祥峈996梁誘ㄛ筍砃煖須氪祡噹ㄐ 羸极抶※淜蜊庈§:碩控桏蝦涳蔬韓誠痰刓岆埤欴 卼翮帠仍監倛缺曌Я務扂捑恦翻校楊巹抎暮 え敵褸怮Э掛遠鰓磁釬鞦蜊萇荌 湮拫韓ㄐ澈羸陔恓眻畦跤恅婓窌溼藝饜陳珅弊よ 陝爵鎔鎔囀聆※閉撰芢熱§ㄛ楷薯陓洘霜妀珛趙 れ菁訧掛陔幛燠с:玃桵傖飲繚Э綴彶坫華莉珛昢鋸囷 イ陬癹劃盪妢衄咡笝賦イ陬庈部茩懂Ч陑撙 漆獲旮①豢啞掀皎ㄩ扂珨毞掀珨毞載乾斕 蹕燠饜薩陔謗堎忑楷汒ㄩ朸韓囮扔鰓疰й肪珨媕 蜓尪艙ㄩ廖怢霧帤懂杅堎囀祥頗棗庤倚糧 2019奻漆陬桯抻奩ㄩ弊莉挋嫌挋XC40 樂噙鰫伄謗躓嫁勤掀桽覃朁疏璊岆※踢禱囧卼§ 襖韓酷祥酷ˋ褪掀郔馮誹醴菴珨ぶ憩猁詻縐阺畛 楊弊逋抭操陎啎聆鳶璋掛撫嗤夢ㄐ資探嫌遜萸婝 2019奻漆陬桯悕痰擘峒織曾/斐賜謠眈 毞漆⑩譎峓饕怍湛⑩譎掩倢憶劑源枑尨睿迣夤 弝橇笢弊疪邆葺蛜痗提疥疰К蠍蝥挋掙瘞磃佳帎滹 о鏍絨翋炟冼奠銴薹芶統溼埡誠凰湮俜⑹ 掉喊躓陬翋豭咂峎那鯙4S虛蔚※煦ぶ督昢煤§蜊靡 澈弊毞卼抎迡棧陔盪妢ㄐ掀潛整氈窒謗湮換も 塘蹕佴尪條珋旯巹囀蟪食玾褻逽滿健Й防岈補啎§ п漆韐伄桽掩景嘔矓※堅給§厙衭ㄩ扂蠅涴憩懂痴 楊羸:匙燮吤譫埏階瞼腔萇盄傻繚麼岆竘楷鳶婐埻秪 笢弊珨撫僅冪撳崝厒Ч麩襓齱〢次鱹艙分奻覃啎聆 陝嫌摯瞳捚鏍笲樟哿尨哏猁⑴曹賂 眭①侇鮵炱牉ˊ拻珨葩堤ㄩ坻硐統樓躉綴馱釬 2019奻漆陬桯ㄩ慇艇F7x淏宒奻庈 彆遙嘟й輔蔥諄輓鐘皆薰兢巠磁遙撫 掉喊SUV眳珗GLE/GLB衙癩陬/EQC謠眈 臟縐悵撰婓咡郗哿埮探湮邟笢閉笭踢肂③掩坻擇橈 わ珛詢奪梑※湮呇§蜊靡※踢膘穛§郔綴淩輛賸潼郜 觓瘍蛌厙\"諧嗣嗣\"堍茠妀跪笱磁埮杶繚秏賤淉習綻瞳 ▲陲僧◎狟殤ˋ淏え弝け拸楊畦溫す怢源婃拸隙茼 埡羸:悵瞳攝兜諉⑩雄釬磁燴茼瓚侉芘衲敖玸雄釬 黰逜16sよ耦忒儂楷票頗啎※拸趼毞抎§爵遜衄贈躇 準粔郔湮萇妀Jumia忳袚癱ㄩ3毞嘖歎梀盟輪200% 桲啡皏湍芶勦蚔陔樓ぞ援縐む伎蟀极踴ч景奀奾 蔭埡ㄐCBA換も咑菩婬擄忑撫綴蝠瑟妢珨晚給 藒韍豜逽瑤奎埸普埣蚘傸捙騊霰溼佴模妗囥秶笛 藝弊冪撳崋繫軗ˋ藻跦湮籵CEO睿ヶ藝薊揣翋炟釭毀覃 藝嘖攫ヶㄩ嗣弇薊揣夥埜蔚蔡趕ぶ硌苤盟戀汔 弊囀こ齪撼俴秷夔る俴陔こ楷票頗厙綻善部翑薯 羲桉賜ㄐ慇腎:砉斕涴笱滅忐扂涴捲赽飲羶獗徹 疏疏峎も吨部NBA盪妢菴珨ㄐ鞠盓勦飲祥褑 2019奻漆陬桯抻奩ㄩ擘痔價攝Huracan釣囑 藝弊茈巖蚳模懂貌掩擇ワ笢源ㄩ俇封й懋迄池 諧※註§ㄐ濘朸芚湍躓嫁俙詢諾砐醴漲躓嫁玸犮韜 DNA眳虜挋伬ㄩ※褪悝笱逜翋砱§秝荌狟腔邧蹟唅侂 鎮佴親ㄩ杻佴嶺蔚婓帤懂12跺堎囀汜莉閉徹50勀謙イ陬 毞踩肅掀忑楷ㄩ怍湛婬奻陝伬馨毞漆摩ょ郔Ч淝 ヶ霤薊靡蔚:蝝阭虯瓛閤蒝摨嚄孝痗隙磁衄儂頗 珨煦笘腔极桄ㄛ類賸珨參鰻鑩馗HEV 橾恄痰盪陔爛た阨誹善懂ㄛ笢弊蚔諦梗酕涴虳岈 厙衭陔樓ぞ髒郣桲啡皏ㄛ莉赽圉爛綴葩堤旯第閥葩朸厒ㄐ Э面森鼲僱櫺割瓚§例1砬藝啋腔歎跡掩闖裁 砩樅-窪伢萸伀謗蔚夼豖AC譙擘у嶺ょ兜嗤5謫忑吨 杻佴嶺隙茼侂狟笢砦芘訧嘖歎視盟坫晜祫2.77% つ衾藝弊揤薯涴珨弊暱郪眽※佫§賸 HYDE奀路珨爛婬羲笢弊挐栳桯珋曾淏茞牷幗 藝弊ほ湮俴CEO掩弊頗攫恀ヶ詢呏橾軞路諾湖 蟀哿坋跺撫撫綴韜笢煦ㄐ涴岆珋砢菴珨 笢弊滇華莉※韓瘀傘矨§帤懂軗岊艘萸 廖怢霧毓迆恮2020ㄐ阰頗岆蜓尪艙諉啤芄 橾鬲朁嘖ㄩ夔瘁湖ぢ4.19藹紸ˋ 鍋堊摩芶眒籵徹誠蝠垀壚捅啎數蔚衾4堎25梲羌撞噯 艘汊hh誑湖螞恅殍ㄩ扂郔赻蚕赻婓 笝衾善賸佽婬獗腔奀緊ㄐ霾峎棕價ヶ濡荅醒 2019臟埮陬桯ㄩ陎闕SVAutobiography 伈杻猁歲腔祥硐衄藝弊珨跺泔桵淏Ь頗れ ※準粔陝爵匙匙§Jumia奻庈忑梛剻癱梀閉70% 郯欀た騑事桯赯T綃楊ˋ 霤傑熒蔚綴湮躑ㄐ醱勤噩芛眻諉惇棉ㄩF***VAR 霤薊竭汜ァㄐ韁夢汜侚桵ヶ匙籪蓒▲脂齫硥蝸 陬わ汁篨鄙船祑湮ㄩ陲瑞崝酗郔嗣珨イ諄陬狟賑4傖 梒赽禊伄迵躓嫁磁桽儐渭笲芄疤驞悈睿睿倳倳珨欴牉ㄐ 踢窅邧邧囮忐笭猁壽諳忑炟習謹呇:絞陑攫淕奀溢渣 俋羸ㄩ肅弊賦旰冪撳酴踢奀ぶ籀眢遠噫潸麵 誧俋繞茠闡爵喃萇ˋ姪諾漈鰡蓒窈衚朵6蝏 2019奻漆陬桯:峒薦僭苂處RZ奻庈/27.38勀れ 2019奻漆陬桯抻奩ㄩTeramontX 蔽竣攝嫌賤埮偶泭机梪硜毓侃韥罋屎導糒賱韇蚙 藝笙酗譟贗м薯穻惚哏嫌:祥玴羋岆※渣昫腔刲﹛ 舜頃膘扢巖杻梗洘珋汔7%斐15跺堎詢 蟀諦ㄐ賽譴婓綻刓7桵城喿漺恅傽羃媕朝艞 靡苺救珛腔坴ㄛ器蹙邈善申Ⅰ綻腑⑹酕悵賞 2019奻漆陬桯抻奩ㄩ掀捚舜S2 笝衾ㄐ柈假哫票統樓恁凅ㄐヶ侐遜衄跺梇寰芄 隴陎湍滯赽奀婈須赶翋畦躲鼴薺呇備剒悵誘帤傖爛 景俀苤煦勦婬磁极ㄐ燠眢瑕錨萸峈紾珨韓④汜 蹕迶瘀輪桽衱纖賸ㄛ逄堤儐佽戁府朊擱窐г賬賬 婦歇:貌倓2018閉10跺芘訧鼠侗奻庈帤懂壽瑩棵岆崝# し彆詢籵笝憤勤樵ㄩ儅埳眒壅腔謗湮CEO蔚勤移鼠斻 笢秏衪:掩芘咂イ陬こ齪掉喊齬菴媼价陬楷雄儂恀枙嗣 弊模陔恓堤唳嫘萇軞擁楷恅蚔牁唳瘍扠惆淏宒笭ゐ 澈荌き滇ㄩ岍埣瘍枙第▲汜捸溺禢晁藐狩羔暲 奾肅儂凳茠种疪筘ㄩ豖悝諶25%蛁聊煤悝煤詢洘湃遴 萵瓮酗峈橾啣枑鼎※悵譟宒§督昢鳳3300豻勀隙惆 2019奻漆陬桯ㄩ珨イ猿泬C-HR曾萇雄唳謠眈 陲儔兜堍最毓見盡隞鼳袙蟔敉鱉鶲敕躉宒絞毞 Facebook婓塘蹕佴婈郣楠遴帤枑鼎蚚誧杅擂湔揣陓# 銘鎮夥源:雁岈頗蠶袧皎馨拫楹党湃遴5.57砬韁30爛# 悵瞳楷桯汁篨鄙鯕3傖峈詢歎華數枑湔億視歎23砬 鎮棧!踏爛艘奻阰賸佽勘!湍覂苤啞鏽柈假躲斕遙 鼠遜赯T綃楊ˋ捶ぱㄩ郯欀た韗畏躆衋恄忏轎斕 岍賜郔湮※邧旯操拸啪§忑滄ㄩ載晞皊腔楷扞怹陎鳶璋 慛堁輾而譙萹繲隗疚承汐晶莉趙茩儂郣 掩ヶ躓衭酴盡饑硌岆柲馮僕溢は衄毞鳳煨佪蠅薯穻 眻僻|笚箄睏瘁牁祤眚晏:帤懂頗芘堤10模※も假陓§ 弝橇笢弊楷票祡К汒隴ㄩ勤す怢囀搚こ督昢姻磄葡 藝弊珨毞嗣砐秶笛渀勤嘉匙藝嘉踡桲壽炵婬汔撰ˋ 峎迂撲袹拿萋鰽蠍屍釂齉挫縭婠畏佳罔勢熁棕悈 縐匙佴價惆豢ㄩ70%腔窪諦馴僻岈璃鏑袧Office穢韌 賒瑞蛌曹ˋ楹捷籟嘖煌煌給狟郔絀眒隙雪閉40% 艇醫濘佴:笚縑魚隴毞衄儂頗奻部羚湒隅敕鯙倬區 砩湮瞳軞燴謂杻ㄩ濂岈賡輷瑀酉紗熏掀捚喳芼 窪坒湮梀!訧莉閉5000砬藝啋哫票ゐ雄鼠侗秶賦凳蛌倰 輪5勀砬厥累﹜48硐嘖き45硐奻梀匙滑杻珨撫僅惟蚻 呤倓O綴掩暮氪恀蒔排ㄐ泭善涴謗跺趼陑飲呯賸 勍輿ㄩ踢艙SERES枑釩珂极桄﹜綴隅秶﹜婬蝠葆腔源宒 弊暱芘俴覃詢笢弊崝酗啎ぶ藝羸:芘訧笢弊腔景毞懂賸 旮僻|掩僕ч芶萸靡弝橇笢弊疪諢偕痗插 2019爛10堎笢弊蔚忑棒撼域CHALLENGEFAM# 詢肅溫堤湮桸ㄩ藩爛祥閉啃啋枑鼎詢儕華芞 隆駁綴躓源毀際鹹赽蔚坴伀漲ㄩ猁繫毆扂猁繫遜ヴ 2019奻漆陬桯ㄩDS侐遴陔夔埭陬倰捚粔忑凅 梨綿姘夢濂繩豌勦晡肣蔽亄豐郪蔚桵岍賜戚 祥岆芶极奧岆髦邧ㄐ陳澈薊勦褡咡堤桵陲儔兜堍頗 毞賞遠噫迵荂僅蛁聊弊わ隆蕾磁釬衪祜 24呡眒駁躓赽眕厙蟋峈靡ぉヴ遜湃掩狪藷劑源蚰眸寥偶 桲陳栠俙韜蔥傖掛刲緒弝け欄炷衄嗣麵 廖怢霧潔諉哫票統恁2020ㄩ鎔逌迖襞猁扂峈怢俜酕岈 笚瑤:奻勀模A謫眕奻斐珛鼠侗笢祥善啃模夔寞耀趙荅瞳